Alantra advises Perrigo on the carve-out and sale of Medgenix 

Oct 2026

Sell-side advisory

New York, London – Alantra has acted as financial advisor to Perrigo Company plc (“Perrigo”) on the carve-out and sale of Medgenix, its Belgian pharmaceutical development and manufacturing subsidiary. The business is now under the ownership of Medgenix Healthcare, a Belgian company established by Magnus Bruhn, Edgard Vermeersch and Jan Peeters. 

Founded in 1926 and based in Wevelgem, Belgium, Medgenix is a pharmaceutical contract development and manufacturing organization (CDMO) specializing in liquid and semi-solid formulations. Its former parent company, Perrigo, is a leading global consumer self-care company with a strong presence in North America and Europe, offering a broad portfolio of over the counter (OTC) healthcare products and well-known brands including Opill, Compeed and Solpadeine. 

Rusty Ray, Managing Partner at Alantra, said: “We’re pleased to have advised Perrigo on the carve-out and sale of Medgenix, building on our established relationship with the company. The transaction marks Medgenix’s return to independent ownership and highlights our team’s expertise in executing complex cross-border divestitures in the consumer healthcare sector.” 

Charles Lanceley, Managing Director at Alantra, said: “We are delighted to advise Perrigo on its second disposal mandate with Alantra in two years. This also marks our 8th deal in the consumer health CDMO sector over the past 18 months, reinforcing Alantra’s position as the leading advisor in the sector.” 

This transaction further reinforces Alantra’s track record in the Consumer Goods & Retail sector, particularly within VMS, Nutrition & Consumer Health. Recent relevant transactions include advising 21st Century Healthcare on its sale to Grant Avenue Capital, CapMan Buyout on the sale of Pharmia to Labomar, Venture Life Group on the sale of its CDMO business to BioDue and Perrigo on the divestment of Richard Bittner to DCC Healthcare.